The Case for Adjuvant Radiation Therapy in Advanced Hodgkin's Disease

References

• O'Connell M J, Martenson J A, Wieand H S, et al. Improving adjuvant therapy for rectal cancer by combined protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502–507
   PubMed Web of Science ®Google Scholar
• Cummings B J. Adjuvant radiation therapy for colorectal cancer. Cancer 1992; 70: 1372–1383
   PubMed Web of Science ®Google Scholar
• Minsky B D, Cohen A M, Kemeny N, et al. Combined modality therapy of rectal cancer: Decreased acute toxicity with a preoperative approach. J Clin Oncol 1992; 10: 1218–1224
   PubMed Web of Science ®Google Scholar
• Bosset J F, Horiot J C. Adjuvant treatment in the curative management of rectal cancer: A critical review of the results of clinical randomized trials. Eur J Cancer 1993; 29: 770–774
   Google Scholar
• Cummings B J. Anal cancer. Int J Radial Oncol Biol Phys 1990; 19: 1309–1315
   Web of Science ®Google Scholar
• Harris J R, Lippman M E, Veronesi U, et al. Breast cancer. N Engl J Med 1992; 327: 319–328, 390–398, 473–480
   PubMed Web of Science ®Google Scholar
• Department of Veterans' Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690
   PubMed Web of Science ®Google Scholar
• Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593–1598
   PubMed Web of Science ®Google Scholar
• Pignon J, Arriagada R, Idhe D C, et al. A meta-analysis of thoracic radiotherapy for small cell lung cancer. N Engl J Med 1992; 327: 1618–1624
   PubMed Web of Science ®Google Scholar
• Strauss G M, Langer M P, Elias A D, et al. Multi-modality treatment of stage IIIA non-small cell lung carcinoma: A critical review of the literature and strategies for future research. J Clin Oncol 1992; 10: 829–838
   PubMed Web of Science ®Google Scholar
• Lilenbaum R C, Green M R. Multi-modality therapy for non-small cell lung cancer. Oncology 1994; 8: 25–36
   PubMedGoogle Scholar
• Tannock I F. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 1989; 16: 83–101
   PubMed Web of Science ®Google Scholar
• Yokes E E. Interactions of chemotherapy and radiation. Semin Oncol 1993; 20: 70–79
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Fischer J J, Papac R J. Theoretical considerations in combinations of localized and systemic therapy for neoplastic diseases. J Theoret Biol 1972; 37: 105–114
   PubMed Web of Science ®Google Scholar
• Frei E, III, Luce J K, Gamble J F, et al. Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission. Ann Intern Med 1973; 79: 376–382
   PubMed Web of Science ®Google Scholar
• Young R C, Cannellos G P, Chabner B A, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978; 42: 1001–1007
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Myrianthopoulos L C. An updated dose response analysis in Hodgkin's disease. Radiother Oncol 1992; 24: 1–13
   PubMed Web of Science ®Google Scholar
• Kaplan H S. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease. Cancer Res 1966; 26: 1221–1224
   PubMed Web of Science ®Google Scholar
• Brincker H, Bentzen S M. A re-analysis of available dose response and time-dose data in Hodgkin' s disease. Radiother Oncol 1994; 30: 227–230
   PubMedGoogle Scholar
• Prosnitz L R, Farber L R, Fischer J J, et al. Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkin's disease. Radiology 1973; 107: 187–193
   PubMed Web of Science ®Google Scholar
• Allavena C, Conroy T, Aletti P, et al. Late cardiopulmonary toxicity after treatment for Hodgkin's disease. Br J Cancer 1992; 65: 908–912
   PubMed Web of Science ®Google Scholar
• Brice P, Tredaniel J, Monsuez J J, et al. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease. Ann Oncol 1991; 2: 73–76
   PubMed Web of Science ®Google Scholar
• Boivin J, Hutchison G B, Lubin J H, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69: 1241–1247
   PubMed Web of Science ®Google Scholar
• Hancock S L, Donaldson S S, Hoppe R T. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11: 1208–1215
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Factors effecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949–1955
   PubMed Web of Science ®Google Scholar
• Hohl R J, Schilsky R L. Non-malignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North 1989; Am3: 331343
   Google Scholar
• Morgan G W, Freeman A P, McLean R G, et al. Late cardiac, thyroid and pulmonary sequalae of mantle radiotherapy for Hodgkin's disease. Int J Radial Oncol Biol Phys 1985; 11: 1925–1931
   Web of Science ®Google Scholar
• Rubin P, Zagars G, Chuang C, et al. Hodgkin's disease: Is there a price for successful treatment?. Int J Radiat Oncol Biol Phys 1986; 12: 153–166
   PubMed Web of Science ®Google Scholar
• Marks L B. The pulmonary effects of thoracic irradiation. Oncology 1994; 8: 89–104
   PubMedGoogle Scholar
• Van Houtte P. Radiation and chemotherapy induced lung toxicity. Int J Radiat Oncol Biol Phys 1987; 13: 647–649
   PubMed Web of Science ®Google Scholar
• Brizel D M, Winer E P, Prosnitz L R, et al. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy. Int J Radiat Oncol Biol Phys 1990; 19: 535–542
   PubMed Web of Science ®Google Scholar
• Hirsch A, vander Els N, Straus D, et al. The effect of ABVD chemotherapy with or without mediastinal irradiation on pulmonary function and symptoms in early stage Hodgkin's disease. J Clin Oncol 1996, (in press)
   PubMed Web of Science ®Google Scholar
• Blayney D W, Longo D L, Young R C, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316: 710–714
   PubMed Web of Science ®Google Scholar
• Kaldor J M, Day M E, Clarke E A, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990; 322: 7–13
   PubMed Web of Science ®Google Scholar
• Lavey R S, Eby N L, Prosnitz L R. Impact on second malignancy risk of the combined use of radiation and chemotherapy forlymphomas. Cancer 1990; 66: 80–88
   PubMed Web of Science ®Google Scholar
• Coleman M, Easton D F, Horowich A, et al. Second malignancies in Hodgkin's disease: The Royal Marsden Hospital experience. Radiother Oncol 1988; 11: 229–238
   PubMed Web of Science ®Google Scholar
• van Leeuwen F E, Chorus A MJ, van den Belt-Dusebolt A W, et al. Leukemia risks following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with Teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 1994; 12: 1063–1073
   PubMed Web of Science ®Google Scholar
• Devereux S, Scalssie T G, Vaughan-Hudson G, et al. Leukemia following treatment for Hodgkin's disease: The experience of the British National Lymphoma Investigation. Br Med J 1990; 301: 1077–1080
   PubMed Web of Science ®Google Scholar
• Henry-Amar M, Deitrich P. Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin North Am 1993; 7: 369–387
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Larsen S O, Struck J, et al. Risk of therapy related leukemia and preleukemia after Hodgkin's disease: Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987; 2: 83–88
   PubMed Web of Science ®Google Scholar
• Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4: 830–837
   PubMed Web of Science ®Google Scholar
• Andrieu J M, Ifrah N, Payen C, et al. Increased risk of secondary acute nonlymphocytic leukemia after extended field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990; 8: 1148–1154
   PubMed Web of Science ®Google Scholar
• Mauch P M, Cannellos G P, Rosenthal D S, et al. Reduction of fatal complications from combined modality therapy in Hodgkin's disease. J Clin Oncol 1985; 3: 501–505
   PubMed Web of Science ®Google Scholar
• Abrahamsen J F, Andersen A, Hannisdal E, et al. Second malignancies after treatment of Hodgkin's disease: The influence of treatment, follow-up time and age. J Clin Oncol 1993; 11: 255–261
   PubMed Web of Science ®Google Scholar
• Boivin J, Hutchison G B, Zaluber A G, et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 1995; 87: 732–741
   PubMed Web of Science ®Google Scholar
• Cimino G, Papa G, Tura S, et al. Second primary cancer following Hodgkin's disease: Updated results of an Italian multicentric study. J Clin Oncol 1991; 9: 432–437
   PubMed Web of Science ®Google Scholar
• Hancock S L, Tucker M A, Hoppe R T. Breast cancer after treatment for Hodgkin's disease. J Natl Cancer Inst 1993; 85: 25–31
   PubMed Web of Science ®Google Scholar
• Kushner B H, Zalubar A, Tan C TC. Second malignancies after childhood Hodgkin's disease: The Memorial Sloan-Kettering Cancer Center experience. Cancer 1988; 62: 1364–1370
   PubMed Web of Science ®Google Scholar
• Swerdlow A J, Douglas A J, Vaughan-Hudson G, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: Analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 1992; 304: 1137–1143
   PubMed Web of Science ®Google Scholar
• Swerdlow A J, Douglas A J, Vaughan-Hudson G, et al. Risk of second primary cancers after Hodgkin's disease in patients in the British National Lymphoma Investigation: Relationships to host factors, histology and stage of Hodgkin's disease and splenectomy. Br J Cancer 1993; 68: 1006–1011
   PubMed Web of Science ®Google Scholar
• Tucker M A. Solid second cancers following Hodgkin's disease. Hematol Oncol Clin North Am 1993; 7: 389–400
   PubMed Web of Science ®Google Scholar
• van Leeuwen F E, Klokman W J, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: A twenty year follow-up study. J Clin Oncol 1994; 12: 312–325
   PubMed Web of Science ®Google Scholar
• Yahalom J, Ryu J, Straus D J, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced stage Hodgkin' s disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9: 2193–2201
   PubMed Web of Science ®Google Scholar
• Koletsky A J, Bertino J R, Farber L R, et al. Second neoplasms in patients with Hodgkin's disease following combined modality therapy: The Yale experience. J Clin Oncol 1986; 4: 311–317
   PubMed Web of Science ®Google Scholar
• Beaty O, Hudson M M, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995; 13: 603–609
   PubMed Web of Science ®Google Scholar
• Tucker M A, Morris J, Boyce J D, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991; 51: 2885–2888
   PubMed Web of Science ®Google Scholar
• Doria R, Holford T, Farber L R, et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 1995; 13: 2016–2022
   PubMed Web of Science ®Google Scholar
• Little J B. Cellular, molecular and carcinogenic effects of radiation. Hematol/Oncol Clin North Am 1993; 7: 337–352
   PubMed Web of Science ®Google Scholar
• Tucker M A, D'angio G J, Boyce J D, et al. Bone sarcoma linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588–593
   PubMed Web of Science ®Google Scholar
• The Basic Science of Oncology, I F Tannock, R P Hill. Pergamon Press, Elmsford, NY 1987
   Google Scholar
• Prosnitz L R, Farber L R, Kapp D S, et al. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data. J Clin Oncol 1988; 6: 603–612
   PubMed Web of Science ®Google Scholar
• Fabian C J, Mansfield C M, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: A Southwest Oncology Group Randomized study. Ann Intern Med 1994; 120: 903–912
   PubMed Web of Science ®Google Scholar
• Radford J A, Cowan R A, Flanagan M, et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940–946
   PubMed Web of Science ®Google Scholar
• Jochelson M, Mauch P, Balikian J, et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3: 637–640
   PubMed Web of Science ®Google Scholar
• Cooper D L, Caride V J, Zloty M, et al. Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy. J Clin Oncol 1993; 11: 1092–1098
   PubMed Web of Science ®Google Scholar
• King S C, Reiman R J, Prosnitz L R. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1994; 12: 306–311
   PubMed Web of Science ®Google Scholar
• Even-Sapir E, Bar-Shalom R, Israel O, et al. Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake. J Clin Oncol 1995; 13: 942–946
   PubMed Web of Science ®Google Scholar
• Longo D L, Young R C, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306
   PubMed Web of Science ®Google Scholar
• Carde P, MacKintosh F R, Rosenberg S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–153
   PubMed Web of Science ®Google Scholar
• Hancock B W, Vaughan Hudson G, Vaughan Hudson B, et al. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. Br J Cancer 1991; 63: 579–582
   PubMed Web of Science ®Google Scholar
• Wagstaff J, Gregory W M, Swindell R, et al. Prognostic factors for survival in stage IIIB and IV Hodgkin's disease. Br J Cancer 1988; 58: 487–492
   PubMed Web of Science ®Google Scholar
• Oza A M, Ganesan T S, Dorreen M, et al. Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years. Br J Cancer 1992; 65: 429–437
   PubMed Web of Science ®Google Scholar
• Prosnitz L R, Roberts K B. Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 1992; 6: 113–128
   PubMedGoogle Scholar
• Pavlovsky S, Santarelli M T, Sackmann M F, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A and B Hodgkin's disease. Ann Oncol 1992; 3: 533–537
   PubMed Web of Science ®Google Scholar
• Crowther D, Wagstaff J, Deakin D, et al. A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease. J Clin Oncol 1984; 2: 892–897
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Kaplan H S. The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962–1984. Int J Radiat Oncol Biol Phys 1985; 11: 5–22
   PubMed Web of Science ®Google Scholar
• Yelle L, Bergsagel D, Basco V, et al. Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. J Clin Oncol 1991; 9: 1983–1993
   PubMed Web of Science ®Google Scholar
• Grozea P N, Depersio E J, Coltman C A, . Chemotherapy alone vs combined modality therapy for stage III disease: A 5-year follow-up of a SWOG study. Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Proceedings of the Second International Conference on Malignant Lymphomas. 1985, F Cavalli, G Bonadonna, M Rozencweig, et al. Martinus Nijhoff Publishing, Boston, MA
   Google Scholar